What is HC Wainwright’s Estimate for ADAP FY2024 Earnings?

Adaptimmune Therapeutics plc (NASDAQ:ADAP) – HC Wainwright upped their FY2024 earnings estimates for shares of Adaptimmune Therapeutics in a research report issued to clients and investors on Thursday, November 14th. HC Wainwright analyst A. He now expects that the biotechnology company will earn ($0.12) per share for the year, up from their prior forecast of ($0.30). HC Wainwright has a “Buy” rating and a $3.50 price objective on the stock. The consensus estimate for Adaptimmune Therapeutics’ current full-year earnings is ($0.19) per share. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ FY2025 earnings at ($0.54) EPS, FY2026 earnings at ($0.42) EPS, FY2027 earnings at ($0.12) EPS and FY2028 earnings at $0.06 EPS.

Several other analysts have also recently issued reports on ADAP. StockNews.com cut Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 14th. Guggenheim lowered their price target on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a report on Friday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $3.16.

Adaptimmune Therapeutics Stock Performance

Shares of Adaptimmune Therapeutics stock opened at $0.60 on Monday. The firm has a market cap of $152.17 million, a PE ratio of -2.70 and a beta of 2.26. Adaptimmune Therapeutics has a 1 year low of $0.42 and a 1 year high of $2.05. The firm’s 50-day simple moving average is $0.87 and its 200-day simple moving average is $1.03. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.09 and a current ratio of 3.85.

Institutional Trading of Adaptimmune Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Fullcircle Wealth LLC bought a new position in Adaptimmune Therapeutics during the 3rd quarter worth $33,000. Vontobel Holding Ltd. lifted its stake in Adaptimmune Therapeutics by 230.8% in the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 30,000 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Adaptimmune Therapeutics during the third quarter valued at $95,000. Boulder Hill Capital Management LP bought a new position in shares of Adaptimmune Therapeutics during the first quarter worth about $143,000. Finally, Jane Street Group LLC increased its holdings in shares of Adaptimmune Therapeutics by 130.4% in the 3rd quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after acquiring an additional 98,581 shares during the period. 31.37% of the stock is currently owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.